Vir Biotechnology reported a narrower-than-expected net loss of $96.3 million for the third quarter of 2026, compared to a $163.1 million loss in the prior year. While total revenues were slightly negative at -$0.19 million due to collaboration adjustments, the company ended the period with $901.3 million in liquidity, bolstered by a significant new strategic partnership in oncology.
Key Highlights
- Topline data from the pivotal Phase 3 ECLIPSE 1 trial for chronic hepatitis delta remains on track for a fourth quarter 2026 readout.
- Research and development expenses declined 47% year-over-year to $80.0 million, primarily driven by the absence of a one-time $75 million milestone payment made in 2025.
- A new collaboration with Gilead provided $90 million in total upfront consideration, including a $65 million cash payment and a $25 million equity investment at a 30% premium.